We concluded that pyridostatin in combination with the DNA‐PKcs inhibitor NU‐7441 and paclitaxel has a specific and potent anti‐BRCA1/2‐deficient tumour activity superior to each compound alone, and to the combination of pyridostatin with each single compound, thereby supporting the potential of this triple combination to be exploited therapeutically in BRCA1/2‐mutated cancer patients. Here, PRKDC is linked to cancer.